Nishimura T, Chihara N, Shirakawa R, Sugai S, Sakamoto T, Nakagawa Y, Aze Y, Shimouchi K, Ozeki Y, Fujita T
Fukui Institute for Safety Research, Ono Pharmaceutical Co., Ltd., Japan.
J Toxicol Sci. 1997 Dec;22 Suppl 3:537-57. doi: 10.2131/jts.22.supplementiii_537.
A perinatal and postnatal study of landiolol hydrochloride (ONO-1101), a novel ultra short acting beta-blocker, was conducted in Sprague-Dawley(SD) rats. ONO-1101 was administered intravenously at a dose level of 0 (control), 25, 50 or 100 mg/kg/day from day 17 of gestation to day 20 after parturition to examine the effects on pregnancy, delivery, lactation and the effects on postnatal growth and development of offspring. In the 100 mg/kg/day group, hypoactivity, reddish lacrimation, clonic convulsion and bradypnea/apnea were observed after administration and 5 animals died in the treatment period, and body weight on day 21 and food consumption on day 14-21 of dam at weaning were lower than control group. In the 50 mg/kg/day group, reddish lacrimation was occasionally seen in some animals. ONO-1101 had no effects on pregnancy, delivery, lactation and necropsy findings or organ weights of dams. In the 100 mg/kg/day group, viability of offspring on day 4 after birth decreased and body weight gain of the suckling suppressed, but those changes recovered after weaning. On the skeletal examination of offspring culled on day 4 after birth, decrease in the mean number of osiffied phalanges of hindpaw and increase in the incidence of unossified talus bone were seen in the 100 mg/kg/day group, however, no delay of ossification was found form the weanling. There were no influence of ONO-1101 on external differentiation, functional, behavioral or learning abilities or reproductive performance in offspring. From the above results, it is estimated that the no-toxic dose level of ONO-1101 under these experimental conditions is 50 mg/kg/day for dam and offspring.
在斯普拉格-道利(SD)大鼠中进行了一项关于新型超短效β受体阻滞剂盐酸兰地洛尔(ONO-1101)的围产期和产后研究。从妊娠第17天至产后第20天,以0(对照)、25、50或100mg/kg/天的剂量水平静脉注射ONO-1101,以研究其对妊娠、分娩、哺乳的影响以及对后代出生后生长发育的影响。在100mg/kg/天组中,给药后观察到活动减少、流泪发红、阵挛性惊厥和呼吸过缓/呼吸暂停,治疗期间有5只动物死亡,断奶时母鼠第21天的体重和第14 - 21天的食物消耗量低于对照组。在50mg/kg/天组中,一些动物偶尔出现流泪发红。ONO-1101对母鼠的妊娠、分娩、哺乳、尸检结果或器官重量没有影响。在100mg/kg/天组中,出生后第4天后代的活力下降,哺乳期间体重增加受到抑制,但断奶后这些变化恢复。在对出生后第4天扑杀的后代进行骨骼检查时发现,100mg/kg/天组后爪骨化趾骨的平均数量减少,距骨未骨化的发生率增加,然而,从断奶幼鼠中未发现骨化延迟。ONO-1101对后代的外部分化、功能、行为或学习能力以及生殖性能没有影响。根据上述结果,估计在这些实验条件下,ONO-1101对母鼠和后代的无毒剂量水平为50mg/kg/天。